Systemic lupus erythematous (SLE) drugs market is anticipated to grow at a significant CAGR during the forecast period. Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease that causes the immune system to attack healthy body tissue. In SLE, the body immune system can affect any part of the body, such as joints, organs, eyes, skin, among others. The major factor for the growth of the market during the forecast period is the high prevalence of autoimmune diseases, particularly systemic lupus erythematous (SLE).
According to the Lupus Foundation of America, 1.5 million Americans, and at least five million people have a form of lupus globally. Additionally, lupus strikes mostly women of childbearing age. However, men, children, and teenagers can also develop lupus. Further, as per the same source, almost 90% of people living with lupus are women and most people develop the disease between the ages of 15-44. Apart from this, there are 16,000 new cases of lupus every year.
To Request a Sample of our Report on Systemic Lupus Erythematous (SLE) Drugs Market: https://www.omrglobal.com/request-sample/systemic-lupus-erythematous-sle-drugs-market
Some major key players in the market include Bristol-Myers Squibb Co., GlaxoSmithKline plc, and Sanofi S.A., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2020, GlaxoSmithKline plc received approval for BENLYSTA (belimumab) by the FDA for the treatment of adult patients with active lupus nephritis. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE).
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Product
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape-Bristol-Myers Squibb Co., GlaxoSmithKline plc,and Sanofi S.A., among others.
A full Report of Systemic Lupus Erythematous (SLE) Drugs Market is Available at: https://www.omrglobal.com/industry-reports/systemic-lupus-erythematous-sle-drugs-market
Systemic Lupus Erythematous (SLE) Drugs Market Report by Segment
By Product
- Corticosteroids
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Anti-Inflammatories
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Antimalarials
- BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
- Immunosuppressive Agents/Immune Modulators
- Anticoagulants
By Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Online Drug Stores
Systemic Lupus Erythematous (SLE) Drugs Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/systemic-lupus-erythematous-sle-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
